Related Experiment Video
Updated: Feb 11, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Alexandra K Rzepecki1, Haiying Cheng2, Beth N McLellan3
1Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Abstract:
The relationship between treatment outcome and cutaneous toxicity induced by anticancer therapy has gained attention in the past decade. In this article, we have provided an overview of the 3 main classes of anticancer agents-specifically, molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics-and described the data evaluating the association between cutaneous toxicity induced by these agents and survival benefit. Although preliminary studies are promising with regard to the potential role of cutaneous toxicities as a surrogate biomarker of efficacy of treatment, larger prospective studies are needed to confirm this relationship. Dermatologists have a unique opportunity to collaborate with oncologists in the multidisciplinary treatment paradigm by helping to identify and manage these dermatologic events in patients with cancer. A heightened awareness of these toxicities is critical, as it can potentially allow recognition of the efficacy of anticancer therapy and may influence treatment decisions and patient outcomes.
Insights
Skin toxicities from cancer treatments like targeted therapies and chemotherapy may indicate treatment effectiveness. Further research is needed, but recognizing these side effects can guide cancer treatment decisions and improve patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Cutaneous toxicity from anticancer therapies is increasingly recognized.
- The link between skin side effects and treatment efficacy is a growing area of research.
Purpose of the Study:
- To review the association between skin toxicities and survival benefit across major anticancer agent classes.
- To highlight the potential of cutaneous toxicities as biomarkers for treatment efficacy.
Main Methods:
- Literature review of studies on molecularly targeted kinase inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapeutics.
- Analysis of data correlating cutaneous toxicity with treatment outcomes and survival.
Main Results:
- Preliminary data suggest a promising association between specific cutaneous toxicities and improved survival.
- The relationship varies across different classes of anticancer agents.
Conclusions:
- Cutaneous toxicities may serve as surrogate biomarkers for anticancer therapy efficacy.
- Larger prospective studies are required to validate these findings.
- Dermatologist-oncologist collaboration is crucial for managing these toxicities and optimizing patient care.
Related Concept Videos
Predicting Reaction Outcomes
Predicting Molecular Geometry
Receiver Operating Characteristic Plot
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Prediction Intervals
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y.
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...

